

**THE EFFECT OF TRANSDERMAL PROPANETRIOL TRINITRATE
ON: NITRIC OXIDE LEVEL, PLASMA THROMBOMODULIN LEVEL,
UMBILICAL AND UTERINE DOPPLER FLOW VELOCIMETRY AND
HYPERTENSION IN THE MANAGEMENT OF E.P.H.GESTOSIS**

THE S I S

Submitted for partial fulfillment of
M.D. Degree in:

OBSTETRICS AND GYNECOLOGY

Presented by

Mohamed Sayed Ali

M.B., B.Ch., & M. Sc (Ain Shams University)



Under the supervision of

Prof. Hamdi Mohamed El-Kabarity

Professor of Obstetrics and Gynecology
Faculty of Medicine
Ain Shams University

618-3
H.S. **Prof. Saied Mohamed Tohami**

Professor of Obstetrics and Gynecology
Faculty of Medicine
Ain Shams University

Dr. Mohamed Ashraf Mohamed Farouk Kortam

Assist. Prof. of Obstetrics and Gynecology
Faculty of Medicine
Ain Shams University

Dr. Mona Ahmed Wahba

Assist. Prof. of Clinical Pathology
Faculty of Medicine
Ain Shams University

FACULTY OF MEDICINE
AIN SHAMS UNIVERSITY
2000

بِسْمِ اللَّهِ الرَّحْمَنِ الرَّحِيمِ

﴿ قَالُوا سُبْحَانَكَ لَا عِلْمَ لَنَا إِلَّا مَا عَلَّمْتَنَا

إِنَّكَ أَنْتَ الْعَلِيمُ الْحَكِيمُ ﴾

صَدَقَ اللَّهُ الْعَظِيمُ

[البقرة : ٣٢]



ACKNOWLEDGEMENT

My words stand short of my supreme gratitude and thanks to Prof. Dr. Hamdi Mohamed El-Kabarity, Professor of Obstetrics & Gynecology, Faculty of Medicine, Ain Shams University, for his continuous supervision, valuable guidance, generous encouragement, help & overall his moral support and kindness that gave me and this work a lift to the scope of light.

Special thanks are due to Prof. Dr. Saied Mohamed Tohami, Professor of Obstetrics & Gynecology, Faculty of Medicine, Ain Shams University, for dedicating so much of his precious time and effort, and for his honest and constant guidance to complete this work.

I am deeply indebted to the great help offered by Assist. Prof. Mohamed Asharaf Mohamed Farouk Kortam, Assist. Professor of Obstetrics & Gynecology, Faculty of Medicine, Ain Shams University; to him I owe many valuable remarks and a lot of precious time and effort, his guidance and kind assistance supported in completing this work.

Special thanks go to Assis. Prof. Mona Ahmed Wahba, Assist. Professor of Clinical Pathology, Faculty of Medicine, Ain Shams University, for her helpful suggestions, unending patience and invaluable assistance.

Mohamed Sayed Ali

ABSTRACT

Objective: To study the effect of nitric oxide donor (propanetriol trinitrate) on E.P.H. gestosis, the associated endothelial cell injury and fetal wellbeing.

Study design: The study comprised 50 pregnant patients between 28 and 38 weeks gestation with the diagnosis of mild or severe E.P.H. gestosis. For every patient a nitroglycerine patch (10mg) releasing transdermal propanetriol trinitrate was attached to skin of the abdomen and replaced daily for the desired duration of treatment.

A venous blood sample was taken from every patient before & immediately after the end of treatment for estimation of plasma nitric oxide levels by ELISA technique (Kits from R&D) systems Inc., Minneapolis MN USA) & plasma thrombomodulin levels using Immubind thrombomodulin ELISA kit (American Diagnostica Inc. greenwich, USA). Doppler ultrasound studies on the umbilical artery (measuring resistance index (RI) were carried out twice-weekly in addition to twice daily evaluation of blood pressure & presence of albuminuria. pregnancy was terminated in cases of severe uncontrolled hypertension after 48 hours of initiation of treatment, fetal distress, impending eclampsia or reaching maturity.

Results: The mean duration of treatment was about 5 weeks with the use of the patches, there was a significant decrease in both plasma thrombomodulin levels & RI by the end of treatment ($P < 0.001$) in addition to a significant increase in plasma nitric oxide levels ($P < 0.001$).

Conclusion: The use of nitric oxide donors provides a good chance for prolongation of pregnancy and improvement of pregnancy outcome in patients with E.P.H. gestosis in terms of decreasing the associated endothelial cell injury & improvement of fetal blood supply.

INDEX

Part	Subject	Page
I	Introduction	1
II	Aim of The Work	4
III	Review of Literature	
	1- Hypertensive disorders in pregnancy	5
	2- Nitric Oxide	43
	3- Endothelial cell injury and thrombomodulin	76
	4- Doppler studies and pregnancy induced hypertension	89
IV	Patients and Methods	112
V	Results	125
VI	Discussion	175
VII	Summary and Conclusion	187
VIII	Recommendations	190
IX	References	191
X	Arabic summary	---

LIST OF TABLES

No.	Title	Page
	A- IN REVIEW	
1	Maternal guidelines for management of preeclampsia	32
2	Fetal guidelines for management of preeclampsia	33
3	Protocol for administration of (MgSo ₄)	37
4	Protocol for administration of phenytoin	38
5	Pharmacologic management of acute hypertension	40
6	Comparison between the constitutive and inducible NOS	50
	B- IN RESULTS	
1	Descriptive data for all patients	125
2	Descriptive data for all patients before start of treatment	126
3	Descriptive data for all patients after treatment	127
4	Statistical difference between the mean blood pressure before and after treatment.	128
5	Statistical difference between thrombomodulin before and after treatment	130
6	Statistical difference between the percent of change in mild and severe E.P.H. gestosis with treatment	132
7	Statistical difference between nitric oxide before and after treatment	134
8	Statistical difference between the percent of change in nitric oxide in mild and severe E.P.H. gestosis with treatment	136
9	Statistical difference between the umbilical artery resistant index before and after treatment	138

10	Statistical difference between the percent of change in resistant index in mild and severe E.P.H. gestosis with treatment	140
11	Comparison between thrombomodulin level at different parities before the start of treatment	142
12	Comparison between nitric oxide level at different parities before the start of treatment	144
13	Comparison between the resistant index of the umbilical artery at different parities before the start of treatment	146
14	Comparison between thrombomodulin levels at different degrees of albuminuria before the treatment	148
15	Statistical comparison between nitric oxide level at different degrees of albuminuria before the treatment	150
16	Statistical comparison between resistant index percentage at different degree of albuminuria before treatment	152
17	Statistical difference between thrombomodulin levels in patients with & without IUGR before treatment	154
18	Statistical difference between nitric oxide level in patients with & without IUGR before treatment	156
19	Statistical difference between resistant index percentage in patient with & without IUGR before treatment	158
20	The correlation between change in TM during treatment and other studied parameters	160
21	The correlation between change in NO during treatment and other studied parameters	165
22	The correlation between change in RI % with treatment and other studied parameters	166
23	The correlation between the thrombomodulin level, resistant index and nitric oxide level before the treatment	170
24	The correlation between the thrombomodulin level, resistant index and nitric oxide after the treatment	173

LIST OF FIGURES

No.	Title	Page
	A- IN REVIEW	
1	NO synthesis	45
2	Scheme shows constitutive release of NO	47
3	Induced NO release	49
3	Biosynthesis of NO from L-arginine and recycling of L-citrulline	53
	B- IN RESULTS	
1	Statistical difference between the mean blood pressure before and after treatment.	129
2	Statistical difference between thrombomodulin before and after treatment	131
3	Statistical difference between the percent of change in mild and severe E.P.H. gestosis with treatment	133
4	Statistical difference between nitric oxide before and after treatment	135
5	Statistical difference between the percent of change in nitric oxide in mild and severe E.P.H. gestosis with treatment	137
6	Statistical difference between the umbilical artery resistant index before and after treatment	139
7	Statistical difference between the percent of change in resistant index in mild and severe E.P.H. gestosis with treatment	141
8	Comparison between thrombomodulin level at different parities before the start of treatment	143
9	Comparison between nitric oxide level at different parities before the start of treatment	145
10	Comparison between the resistant index of the umbilical artery at different parities before the start of treatment	147

11	Comparison between thrombomodulin levels at different degrees of albuminuria before the treatment	149
12	Statistical comparison between nitric oxide level at different degrees of albuminuria before the treatment	151
13	Statistical comparison between resistant index percentage at different degree of albuminuria before treatment	153
14	Statistical difference between thrombomodulin levels in patients with & without IUGR before treatment	155
15	Statistical difference between nitric oxide level in patients with & without IUGR before treatment	157
16	Statistical difference between resistant index percentage in patient with & without IUGR before treatment	159
17	Regression analysis showing correlation between duration of treatment and the change in TM during treatment	161
18	Regression analysis showing correlation between SBP and the change in TM during treatment	162
19	Regression analysis showing correlation between DBP and the change in TM during treatment	163
20	Regression analysis showing correlation between urinary albumin and the change in TM during treatment	164
21	Regression analysis showing correlation between SBP and the change in RI during treatment	167
22	Regression analysis showing correlation between DBP and the change in RI during treatment	168
23	Regression analysis showing correlation between urinary albumin and the change in RI during treatment	169
24	Regression analysis showing correlation between NO-B & TM-B among patient group.	171
25	Regression analysis showing correlation between TM-A & NO-A among patient group.	173
26	Regression analysis showing correlation between NO-A & RI-A among patient group.	174

LIST OF ABBREVIATIONS

A.C.O.G	American College of Obstetrician and Gynecologists
ADMA	Assymmetric dimethyl L-arginine
ADP	Adenosine diphosphate
APC	Activated protein C
ARDS	Adult respiratory distress syndrome
ATP	Adenosine triphosphate
C.N.S.	Central nervous system
c-AMP	Cyclic-adenosine monophosphate
c-DNA	Cyclic-deoxy ribonucleic acid
c-NOS	Constitutive nitric oxide synthetase
CW	Continuous wave
D.I.C	Disseminated intravascular coagulopathy
DM	Diabetes mellitus
E.P.H.	Edema, proteinuria and hypertension
EDRF	Endothelial derived relaxation factor
EGF	Epidermal growth factor
F.S.H.	Follicular stimulating hormones
FHR	Fetal heart rate
FWV	Flow velocity wave form
GnRH	Gonadotrophin releasing hormones
GTN	Glyceryl trinitrate
HELLP	Hemolysis, elevated liver enzymes and low platelet count
HPV	Hypoxic pulmonary vasoconstriction
HRP	Horse radish peroxidase
IL	Interleukin
i-NOS	Inducible nitric oxide synthetase
ISMN	Isosorbide mononitrate

ISSHP	International society for study of hypertension in pregnancy
IUGR	Intrauterine growth retardation
IUK:Cr	Inactive urinary kallikrein to creatinine ratio
L.H.	Luteinizing hormone
LDL	Low density lipoprotein
L-NAME	N ^G nitro-L-arginic methyl ester
L-NMME	N ⁸ monomethyl-L-arginine
MAP	Mean arterial pressure
m-RNA	Messenger ribonucleic acid
NAC	N-acetyl cysteine
NANC	Non-adrenergic non-cholinergic neurones
NO	Nitric oxide
NOS	Nitric oxide synthetase
P.I.	Pulsatility index
P.I.H	Pregnancy induced hypertension
PAI-3	Plasminogen activator inhibitor-3
PCR	Polymerase chain reaction
PG	Prostaglandin
PW	Pulsed wave
R.I.	Resistant index
RPMC	Rat peritoneal mast cells
S.L.E	Systemic lupus erythematosus
S.N.P.	Sodium nitroprusside
S/D	Systolic diastolic ratio
TM	Thrombomodulin
TMB	Tetra-methyl benzidine
TNF	Tumour necrosis factor
TXA2	Thromboxane A2



INTRODUCTION

INTRODUCTION

Preeclampsia is a multisystemic pregnancy specific disorder, defined clinically as a syndrome of gestational hypertension, excessive proteinuria and/or generalised oedema [Taylor et al., 1996].

Hypertension is the most common medical disorder associated with pregnancy and preeclampsia constitutes two thirds of cases of hypertension with pregnancy [Seligman et al., 1994]. Hypertensive disorders complicating pregnancy are common and along with haemorrhage and infection, they form a deadly triade that is responsible for a large number of maternal deaths [Cunningham et al., 1993].

Investigation into the pathophysiology of pregnancy induced hypertension revealed that it is a syndrome of increased peripheral vascular resistance, coagulation abnormality, alteration in prostaglandin, nitric oxide (NO), lipid metabolism and tumour necrosis factor. It is considered to be a complex endothelial cell dysfunction which results in disturbance of the delicate balance between vasodilators such as prostacyclin and nitric oxide on one hand and vasoconstrictors such as angiotensin II, thromboxane A2 and endothelin on the other hand. Similarly, the balance between platelet activating and inhibiting factors has to be considered in the over-all function and picture of the disease [Morris et al., 1996].

Endothelium-derived nitric oxide is proposed to play an important role in the lowering of the peripheral vascular resistance in normal pregnancy. In women with preeclampsia, the function of the endothelium is compromised and it is suggested that reduction of nitric oxide synthesis may contribute to the elevation of the blood pressure and activation of the coagulation pathway. also increased levels of factor VIII-related antigen and fibronectin play a role in the pathogenesis [Ballegeer *et al.*, 1990].

An elevated level of nitric oxide throughout pregnancy in normotensive pregnant women contributes to maternal vasodilatation, immunosuppression and maintenance of uterine relaxation. Among the hypertensive disorders, the difference in the clinical features between patients with essential hypertension may be due to plasma concentration of NO [Nobunaga *et al.*, 1996].

Local production of the endogenous vasodilator nitric oxide is important for fetoplacental circulation and reduced production of this substance has been demonstrated in endothelial cells from the umbilical cord in pregnancy-induced hypertension [Pinto *et al.*, 1991]. Circulating level of nitrate (metabolite of nitric oxide) have been found to be decreased in patients with preeclampsia [Seligman *et al.*, 1994].

Thrombomodulin is one of the important biomarkers of endothelial cell damage and can be used for assessment of severity, progression or regression of pregnancy induced hypertension [Shaarawy *et al.*, 1996].

Introduction